MX2022013615A - Inhibidores de macrociclo de peptidilarginina deiminasas. - Google Patents

Inhibidores de macrociclo de peptidilarginina deiminasas.

Info

Publication number
MX2022013615A
MX2022013615A MX2022013615A MX2022013615A MX2022013615A MX 2022013615 A MX2022013615 A MX 2022013615A MX 2022013615 A MX2022013615 A MX 2022013615A MX 2022013615 A MX2022013615 A MX 2022013615A MX 2022013615 A MX2022013615 A MX 2022013615A
Authority
MX
Mexico
Prior art keywords
compounds
peptidylarginine
deiminases
macrocyclic inhibitors
peptidylarginine deiminases
Prior art date
Application number
MX2022013615A
Other languages
English (en)
Inventor
Petr Jansa
James G Taylor
Roland D Saito
Adam J Schrier
Jennifer A Treiberg
Jennifer A Loyer-Drew
Hyung-Jung Pyun
Stephane Perreault
Gary B Phillips
Veldhuizen Joshua J Van
Eda Y Canales
Weng K Chang
Laurent P Debien
Luisruben P Martinez
Michael S Sangi
Marina E Shatskikh
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2022013615A publication Critical patent/MX2022013615A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems

Abstract

La presente descripción se relaciona con compuestos novedosos para usarse en el tratamiento terapéutico de una enfermedad asociada con las peptidilarginina deiminasas (PAD), tal como peptidilarginina deiminasa tipo 4 (PAD4). La presente descripción también se relaciona con procesos e intermedios para la preparación de tales compuestos, métodos de uso de tales compuestos y composiciones farmacéuticas que comprenden los compuestos descritos en la presente descripción.
MX2022013615A 2020-04-30 2021-04-28 Inhibidores de macrociclo de peptidilarginina deiminasas. MX2022013615A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063018411P 2020-04-30 2020-04-30
US202063129430P 2020-12-22 2020-12-22
PCT/US2021/029557 WO2021222353A1 (en) 2020-04-30 2021-04-28 Macrocyclic inhibitors of peptidylarginine deiminases

Publications (1)

Publication Number Publication Date
MX2022013615A true MX2022013615A (es) 2022-11-16

Family

ID=76181198

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013615A MX2022013615A (es) 2020-04-30 2021-04-28 Inhibidores de macrociclo de peptidilarginina deiminasas.

Country Status (17)

Country Link
US (1) US20230002412A1 (es)
EP (1) EP4143189A1 (es)
JP (1) JP2023524036A (es)
KR (1) KR20230004810A (es)
CN (1) CN115551862B (es)
AU (1) AU2021265110B2 (es)
BR (1) BR112022021963A2 (es)
CA (1) CA3177532A1 (es)
CL (1) CL2022002990A1 (es)
CO (1) CO2022015307A2 (es)
CR (1) CR20220550A (es)
DO (1) DOP2022000235A (es)
IL (1) IL296923A (es)
MX (1) MX2022013615A (es)
PE (1) PE20230488A1 (es)
TW (1) TWI815110B (es)
WO (1) WO2021222353A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202241884A (zh) 2020-12-22 2022-11-01 美商基利科學股份有限公司 肽基精胺酸去亞胺酶之抑制劑
WO2023083365A1 (en) 2021-11-15 2023-05-19 Qilu Regor Therapeutics Inc. Pad4 inhibitors and use thereof
WO2024008745A1 (en) 2022-07-05 2024-01-11 Institut National de la Santé et de la Recherche Médicale Methods and composition to identify and treat subjects resisting to chemotherapy treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3821540A1 (de) 1988-06-25 1989-12-28 Boehringer Mannheim Gmbh Neue sulfonamide, verfahren zu ihrer herstellung sowie solche sulfonamide enthaltende arzneimittel
BRPI0808888B8 (pt) 2007-03-12 2021-05-25 Cytopia Res Pty Ltd composto de fenil amino pirimidina para uso no tratamento de uma doença associada à quinase, processo para a preparação do composto, composição farmacêutica, e, implante
PE20081882A1 (es) 2007-03-15 2008-12-27 Schering Corp Derivados de piridazinona utiles como inhibidores de glucano sintasa
GB201106520D0 (en) 2011-04-18 2011-06-01 Numedicus Ltd Pharmaceutical compounds
DK2877467T3 (en) * 2012-07-26 2017-02-13 Glaxo Group Ltd 2- (AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS
EA033680B1 (ru) * 2015-05-21 2019-11-15 Glaxosmithkline Ip Dev Ltd Производные бензоимидазола в качестве ингибиторов pad4
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
MX2018009773A (es) * 2016-02-23 2018-11-29 Padlock Therapeutics Inc Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
WO2018022897A1 (en) * 2016-07-27 2018-02-01 Padlock Therapeutics, Inc. Covalent inhibitors of pad4
US11833156B2 (en) * 2017-09-22 2023-12-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
FI3697785T3 (fi) * 2017-10-18 2023-04-03 Jubilant Epipad LLC Imidatsopyridiiniyhdisteitä pad:n estäjinä
TWI762769B (zh) * 2018-02-26 2022-05-01 大陸商藥捷安康(南京)科技股份有限公司 肽醯精胺酸脫亞胺酶抑制劑及其用途
MX2021001565A (es) * 2018-08-08 2021-04-19 Bristol Myers Squibb Co Inhibidores tipo indol y azaindol de enzimas peptidil arginina deiminasas (pad).
US20220348562A1 (en) * 2018-08-08 2022-11-03 Bristol-Myers Squibb Company Benzimidazole inhibitors of pad enzymes
JP2023512557A (ja) * 2020-02-06 2023-03-27 ブリストル－マイヤーズ スクイブ カンパニー 免疫抑制剤として有用な大環状ｐａｄ４阻害剤
TW202140477A (zh) * 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環ｐａｄ４抑制劑

Also Published As

Publication number Publication date
JP2023524036A (ja) 2023-06-08
TWI815110B (zh) 2023-09-11
CL2022002990A1 (es) 2023-07-14
KR20230004810A (ko) 2023-01-06
EP4143189A1 (en) 2023-03-08
US20230002412A1 (en) 2023-01-05
CO2022015307A2 (es) 2023-02-16
PE20230488A1 (es) 2023-03-21
CR20220550A (es) 2022-12-15
DOP2022000235A (es) 2022-11-30
BR112022021963A2 (pt) 2022-12-13
CN115551862B (zh) 2024-04-12
AU2021265110B2 (en) 2023-08-17
WO2021222353A1 (en) 2021-11-04
CA3177532A1 (en) 2021-11-04
CN115551862A (zh) 2022-12-30
AU2021265110A1 (en) 2022-10-27
IL296923A (en) 2022-12-01
TW202206431A (zh) 2022-02-16

Similar Documents

Publication Publication Date Title
MX2022013615A (es) Inhibidores de macrociclo de peptidilarginina deiminasas.
TW200510375A (en) New compounds
TW200626601A (en) Novel compounds
EP1624874A4 (en) 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IN THE TREATMENT OR PREVENTION OF DIABETES
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
EP1490335A4 (en) HETEROCYCLIC BETA-AMINO DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
WO2003082853A8 (en) New compounds
PL1789398T3 (pl) Pochodne 2-amino-chinazoliny użyteczne jako inhibitory ß-sekretazy (BACE)
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
IS7817A (is) Fenýlalanín afleiður sem dípeptidýl peptíðasa hindrar til að meðhöndla eða fyrirbyggja sykursýki.
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BR0009167A (pt) Inibidores de enzima impdh
MY143795A (en) Tetrahydropyridoindole derivatives
MX2009008228A (es) N-adamantil benzamidas como inhibidores de la dehidrogenasa 11-beta-hidroxiesteroide.
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
TW200606164A (en) New compounds
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
GB0222514D0 (en) Organic compounds
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
UA89067C2 (ru) Производные гидантоина, полезные как ингибиторы металлопротеиназ
MXPA05012675A (es) Compuestos de hidroxiamidina e hidroxiguanidina como inhibidores de urocinasa.
MX2023003264A (es) Inhibidores de cdk y su uso como productos fármaceuticos.